| Price | 8.60p on 20-11-2025 at 06:00:01 |
|---|---|
| Change | 0.00p 0% |
| Buy | 0.00p |
| Sell | 0.00p |
| Last Trade: | Sell 40,000.00 at 8.60p |
| Day's Volume: | 0 |
| Last Close: | 8.60p |
| Open: | 0.00p |
| ISIN: | GB00B02LCQ05 |
| Day's Range | 0.00p - 0.00p |
| 52wk Range: | 5.00p - 9.00p |
| Market Capitalisation: | £528.16m |
| VWAP: | 0.00p |
| Shares in Issue: | 6.14b |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Allergy Thera. (AGY) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Sell* | 40,000 | 8.60p | Uncrossing Trade |
16:35:16 - 19-Nov-25 |
| Sell* | 30,000 | 8.675p | Ordinary |
16:03:23 - 19-Nov-25 |
| Sell* | 50,000 | 8.675p | Ordinary |
14:39:01 - 19-Nov-25 |
| Sell* | 17,251 | 8.70p | Ordinary |
14:29:35 - 19-Nov-25 |
| Unknown* | 95,000 | 8.00p | Ordinary |
14:24:42 - 19-Nov-25 |
| Sell* | 15,691 | 8.255p | Ordinary |
14:17:05 - 19-Nov-25 |
| Buy* | 16,000 | 8.80p | Suspected BUY Trade |
14:00:06 - 19-Nov-25 |
| Buy* | 10,659 | 8.80p | Ordinary |
11:41:43 - 19-Nov-25 |
| Sell* | 8,000 | 8.70p | Uncrossing Trade |
11:00:16 - 19-Nov-25 |
| Buy* | 1 | 8.8677p | Ordinary |
10:45:25 - 19-Nov-25 |
Allergy Thera. (AGY) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 6th Nov 2025 7:22 am | RNS | Company to Evaluate Dual Listing on HKEX |
| 30th Oct 2025 7:00 am | RNS | G308 Phase III Year 2 Patient Screening Starts |
| 29th Oct 2025 7:00 am | RNS | Warrant Exercise and Paydown of Debt |
| 16th Oct 2025 7:00 am | RNS | Further progress in Phase I/IIa PROTECT trial |
| 31st Jul 2025 7:00 am | RNS-R | Grass MATA MPL Publications in Allergy Journal |
| 21st Jul 2025 7:00 am | RNS | Trading update for the year ended 30 June 2025 |
| 11th Jul 2025 7:00 am | RNS | PDMR Dealings |
| 13th Jun 2025 7:00 am | RNS-R | Allergy Therapeutics presents findings at EAACI |
| 10th Jun 2025 7:04 am | RNS-R | EAACI Early Career Research Award |
| 31st Mar 2025 7:00 am | RNS | Interim Results for six months ended 31 Dec 2024 |
